E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells.
To assess the lymphoid tumorigenic potential of bcl-2, mice of five independent strains expressing a bcl-2 transgene in B and/or T cells were monitored for disease up to 12 months of age. Lymphoma prevalence was minimal in the T lineage but significant, although low (3-15%), in the B lineage. The principal types of tumors were plasmacytomas secreting immunoglobulin and novel lymphomas that expressed markers such as Sca-1, CD4, Thy-1, CD34 and CD45(B220), consistent with an origin very early in B-lymphoid development. Rearrangement of the c-myc gene was common in the plasmacytomas, implying a synergistic role for myc and bcl-2 in their etiology, but was not detected in the lymphomas.
Strasser
A
A
Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Australia.
Harris
A W
AW
Cory
S
S
D000818:Animals; D000921:Antibody-Producing Cells / Q000473:pathology*; D001402:B-Lymphocytes / Q000473:pathology*; D002471:Cell Transformation, Neoplastic; D015321:Gene Rearrangement; D016259:Genes, myc; D008223:Lymphoma / Q000209:etiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010954:Plasmacytoma / Q000209:etiology; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D019253:Proto-Oncogene Proteins c-bcl-2; D011519:Proto-Oncogenes; D013601:T-Lymphocytes / Q000473:pathology*
D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2